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1. Introduction
Neurodegenerative diseases cover a wide range of neurogenetic disorders including Amyo‐
trophic Lateral Sclerosis (ALS), Alzheimer’s disease (AD), Huntington’s disease (HD), the
spinocerebellar ataxias, inherited prion diseases, the inherited neuropathies, and muscular
dystrophies among others.
In particular, ALS belongs to the group of motor neuron diseases, involving the loss of cortex,
brainstem, and spinal cord motor neurons that result in muscle paralysis [1]. Motor neurons,
which are localized in the brain, brainstem and spinal cord, behave as a crucial links between
the nervous system and the voluntary muscles of the body, as they let synaptic signals travel
from upper motor neurons in the brain to lower motor neurons in the spinal cord and finally
to muscles. In accordance with the revised El Escorial criteria [2], both the upper motor neu‐
rons and the lower motor neurons degenerate or die in ALS, and as a consequence the com‐
munication between neuron and muscle is lost, prompting the progressive muscle weakening
and the appearance of fasciculations. In the later stages of the disease, patients become para‐
lyzed although the disease usually does not impair a person's mind or intelligence.
Nowadays, the cause of ALS and its early manifestations still remain to be elucidated. The
pathophysiological mechanisms that prompt the neurodegenerative process in both familial
(FALS) and sporadic (SALS) ALS are unknown. However, there is growing evidence that
the pathogenic process involved in ALS are multifactorial and include oxidative stress, glu‐
tamate excitotoxicity, mitochondrial dysfunction, axonal transport systems and dysfunction
of glial cells, yielding the damage of critical proteins and organelles in the motor neuron
triggering the neurodegeneration [3]. Due to the fact that FALS and SALS share clinical and
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pathological signs, the understanding of the pathophysiological process in FALS would pro‐
vide a better understanding of the neurodegenerative mechanisms in SALS.
FALS follows a predominantly autosomal dominant pattern, while in SALS genetic factors
that take place sporadically contribute to its pathogenesis. The majority of ALS cases are
sporadic and 5-10% of cases correspond to FALS. Although the ages of onset of FALS, which
follow a normal Gaussian distribution, correspond to a decade earlier than for SALS cases
which have an age dependent incidence, males and females are affected equally in FALS [4].
The most significant candidate genes for SALS include VEGF (vascular endothelial growth
factor), angiogenin (ALS9), paraoxonoase, neurofilaments, peripherin and SMN (spinal muscular
atrophy). Although ALS9, paraoxonase, neurofilaments, peripherin and SMN mutations have
been found in ALS patients, except for VEGF mutations, these genes may play a small role in
the pathogenesis of ALS and previous studies are conflicting [5].
Regarding FALS candidate genes, the mutations in the copper/zinc superoxide-dismutase-1
gene (SOD1), Tar DNA-binding protein gene (TARDBP) and in the most recent discovered
DNA/RNA-binding protein called FUS (fused in sarcoma) or TLS (translocation in liposarco‐
ma) produce the typical adult onset ALS phenotype. Other candidate genes that have been
described in genome association studies of FALS include dynactin, senataxin (ALS4) and
VAPB (ALS8) (VAMP/synaptobrevin-associated membrane protein B gene) [5,6].
The pathophysiology of SOD1 mutations is probably the most studied one. Many hypothe‐
ses have been suggested and reinforced in transgenic mouse models that overexpress the
mutated SOD1 gene and therefore develop an ALS-like syndrome. Among the proposed
mechanisms that support these hypotheses are the toxic gain of function of the mutated
SOD1 enzyme, which mainly increases the production of hydroxyl and free radicals, yield‐
ing improper binding metal properties, oxidative stress and inflammation induced by upre‐
gulation of proinflammatory cytokines [7,8]. Alternative hypothesis also suggested a
conformational instability and misfolding of the SOD1 peptide, forming intracellular aggre‐
gates which have been reported in motor neuron and glial cells [9].
Neurotrophic factors have been initially identified as potential therapeutic agents in the
treatment of ALS, opening the door to a new tool for the treatment of motor neuron diseases
[10]. Based on previous studies ciliary and glial derived neurotrophic factors, insulin-like
growth factor (IGF-1) and erythropoietin improved motor behaviour and reduce motor neu‐
ron loss, astrocyte and microglia activation in preclinical animal models [11], albeit clinical
trials in ALS patients showed lack of therapeutic efficacy [12].
The failure of standard treatments in ALS could rely on the inappropriate route of adminis‐
tration and/or the poor bioavailability of molecules to the target cell [13]. The subcutaneous
and intrathecal delivery of neurotrophic factors can cause adverse side effects such as
weight loss, fever, cough, fatigue and behavioral changes [14], whereas viral gene therapy
based on the use of an adeno-associated virus or lentivirus vectors is more efficient than the
neurotrophic factor delivery but can induce several inherent hazards [15].
An alternative strategy that effectively reaches motor neurons, can exert neuroprotective prop‐
erties and does not show such adverse side effects implies the use of the nontoxic fragment C
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(TTC) of tetanus toxin. Tetanus toxin is a neurotoxin produced by Clostridium tetani, an anaero‐
bic bacterium whose spores are commonly found in soil and animal waste. This toxin affects
the nervous system and causes generalized muscle contractions, called titanic spasms [16, 17].
Tetanus toxin is a single peptide of approximately 150 kDa, which consists of 1315 amino-acid
residues. The toxin forms a two-chain activated molecule composed of a heavy chain (HC) and
a light chain (LC) linked by a disulfide bond. The catalytic domain of the toxin resides in the LC,
while the translocation and receptor-binding domains are present in HC [18–21] (Figure 1).
Tetanus and botulinum toxins are zinc metalloproteases that cleave SNARE (soluble NSF at‐
tachment receptor) proteins, which interfere with the fusion of synaptic vesicles to the plasma
membrane and ultimately blocks neurotransmitter release in nerve cells [22].
The nature of the action of tetanus toxin has been widely described in different animal mod‐
els [23–28], exploring its effect not only in the spinal cord but also in the cerebral cortex [29].
One of the unique characteristics of tetanus toxin is that it can be transported retrogradely to
the central nervous system and shows remarkable affinity and specificity to neuronal termi‐
nals. The ganglioside-recognition domain in the C-terminal region of HC allows the toxin to
be internalized into the neuron at the neuromuscular junction where it enters the axonal ret‐
rograde transport pathway and is subsequently transported to the neuronal soma in the
CNS [30,31]. Once the toxin reaches the cytoplasm, it specifically cleaves neuronal proteins
integral to vesicular trafficking and neurotransmitter release. In particular, the synaptic vesi‐
cle protein synaptobrevin (VAMP) is the target of tetanus toxin. This protein belongs to a
family of proteins that facilitate exocytosis in neurons known as SNARE proteins. The other
members of this family are syntaxin and SNAP-25, which are the main molecular targets of
botulinum toxin. SNARE proteins are formed by coiled-coil interactions of the alpha-helices
of its members, which is required for membrane fusion [32–35].
Figure 1. Diagram of the tetanus toxin molecule. The targeting and the translocation domains are located in the
heavy-chain (HC), whereas the catalytic domain is located in the light-chain (LC) of the molecule. Its proteolytic activity
is Zn2+-dependent, and heavy-metal chelators generate inactive apo-neurotoxins. TTC is approximately 50 KDa and re‐
sides in the HC of the toxin. The ganglioside-recognition domain in TTC allows the toxin to be internalized into the
neuron [35].
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From the gene therapy point of view, the most interesting part of the toxin that must be out‐
standing is TTC. This fragment of the toxin is located in the HC of tetanus toxin molecule
and it plays an important role in the neuronal internalization (Figure 1). In fact, TTC main‐
tains transport properties of the native tetanus toxin without causing toxic effects, in such a
way that in the absence of TTC, the toxin retains little ability to paralyze neuromuscular
transmission [35,36].
The trans-synaptic transport of TTC was intensively studied in one of the best-characterized
systems, the primary visual pathway [37, 38], confirming its capacity as a carrier once it was
injected intramuscularly [39-41]. Furthermore, the possibility of constructing recombinant
molecules with TTC has opened the door to an interesting research field, the discovery of
neuro-anatomical tracers, whose main purpose is to map synaptic connections between neu‐
ronal cells.
One of the most well-known recombinant proteins that have been used for this purpose is
the protein encoded by lacZ-TTC. This protein has been tested in vitro and in vivo to deter‐
mine its activity in the hypoglossal system, and the detection of the labeled motor neurons
was dependent on time post-injection [40-42]. Since neuronal integrity is crucial for TTC in‐
ternalization, the transneuronal molecular pathway at neuromuscular junctions was inten‐
sively studied using this recombinant protein [43]. The protein was detected not only in the
neuromuscular junction postsynaptic side but also the soma of the motor neuron, away
from the active zones in large uncoated vesicles.
The advances in the understanding of these recombinant proteins have paved the way for
new therapeutic approaches using TTC as a carrier of molecules to ameliorate the disease
process of motor neuron diseases, neuropathies and pain. As an example, several proteins
conjugated to TTC that have been used to study neuronal internalization in vitro and in vivo
are horseradish peroxidise (HPRT), glucose oxidase (GO), green fluorescent protein (GFP), β
-Nacetylhexosaminidase-A (HEXA), superoxide dismutase 1 (SOD1), survival motor neuron
1 (SMN1), cardiotrophin-1 (CT1), B-cell lymphomaextra large (Bcl-xL), IGF-1, glial derived
neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) [17]. More re‐
cently, a novel multi-component nanoparticle system using polyethylene imine (PEI) has
been evaluated to elicit the expression of BDNF in neuronal cell lines [44].
Apart from the carrier properties of TTC, the neuroprotective nature of TTC was one of the
best kept properties to discover.
The neurotrophin family has been shown to regulate survival, development and functional
aspects of neurons in the central and peripheral nervous systems through the activation of
one or more of the three members of the receptor tyrosine kinases (TrkA, TrkB, and TrkC) in
cooperation with p75NTR [45-48]. Nerve growth factor (NGF) can bind to the TrkA receptor or
a complex of TrkA and p75NTR [45], BDNF and neurotrophin-4/5 can bind to TrkB, and neuro‐
trophin-3 binds to TrkC. Interestingly, the retrograde pathway of TTC is shared by p75NTR,
TrkB and BDNF, which is strongly dependent on the activities of the small GTPases Rab5
and Rab7 [49], therefore TTC alone might have a neuroprotective role and therefore it can be
a valuable non-viral therapeutic agent in ALS.
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2. Neuroprotective nature of TTC
Many authors have suggested that the trans-synaptic transcytosis pathway used by tetanus
toxin was most likely “designed” for the trafficking of trophic factors through a chain of
connected neurons [50]. Furthermore, two trophic factors, GDNF and BDNF, have been re‐
ported to possess similar trans-synaptic transcytotic properties to those of tetanus toxin [51].
Tetanus toxin can induce an increase in serotonin synthesis in the central nervous system,
suggesting that the toxin-affected serotonergic innervation in the perinatal rat brain can trig‐
ger the translocation of calcium phosphatidylserine-dependent protein kinase C (PKC) [52].
In particular, tetanus toxin is able to alter a component involving inositol phospholipid hy‐
drolysis, which is associated with PKC activity translocation [53,54]. In addition to this
translocation, an enhancement of the tyrosine phosphorylation of the tyrosine receptor
TrkA, phospholipase C (PLCγ-1) and ERK-1/2 can be also observed [55]. Due to the fact that
TTC can stimulate the PLC-mediated hydrolysis of phosphoinositides in rat brain neurons,
TTC seems to modulate some signaling pathways involving the transport of serotonin [56].
Moreover, the activation of intracellular pathways related to the PLCγ-1 phosphorylation
and activation of PKC isoforms and the kinases Akt (at Ser 473 and Thr 308) and ERK-1/2 (at
Thr 202/Tyr 204) is induced by TTC in rat brain synaptosomes and cultured cortical neurons.
This signal pathway activation is dependent on time and concentration, therefore TTC can
exert neuroprotective effects, activating TrkA and TrkB receptors in a similar manner as do
NGF and BDNF or neurotrophin-4/5 [57,58].
The neuroprotective role of TTC is also supported by the fact that it can also protect cerebel‐
lar granular cells against potassium deprivation-induced apoptotic death [59] and act as a
neuroprotector in a model of 1-methyl-4-phenylpyridinium (MPP+)-triggered apoptosis, en‐
hancing the survival pathways in rats with a dopaminergic lesion and improving different
motor behaviors. Particularly, TTC is able to induce Ser 112 and Ser 136 BAD phosphoryla‐
tion, activate the transcription factor NF-κB, which prevents neuronal death, and induce a
decrease in the release of cytochrome c and, consequently, a reduction in the activation of
procaspase-3 and chromatin condensation [60,61].
More recently, the nature of TTC described by Longstreth and colleagues [62] and Larsen
and colleagues [63], based on its stability to reach motor neurons specifically through the
retrograde axonal transport system, has been reinforced as a potential neuroprotective agent
in previous in vivo studies of gene and protein expression after injection of plasmid-DNA in
transgenic SOD1G93A mice, which carries the mutation G93A in human superoxide dismutase
1 (SOD1) [64]. These studies suggested that intramuscular naked-DNA TTC gene therapy
administered into neurodegenerative mouse model delayed the onset of symptoms (by ap‐
proximately 5 days), prolonged survival (by approximately 13 days) and improved the mo‐
tor function activity in TTC-treated mice throughout disease progression, by increasing
numbers of surviving motor neurons (Figure 2).
Gene Therapy Based on Fragment C of Tetanus Toxin in ALS: A Promising Neuroprotective Strategy for the Bench…
http://dx.doi.org/10.5772/52896
253
Figure 2. Functional and survival effect under TTC treatment. Intramuscular injection of TTC-encoding plasmid in
SOD1G93A mice (grey bars) delays significantly disease onset and mortality compared to the control group (*p<0,05,
error barrs indicate SEM) (Reprinted from Orphanet J. Rare Dis., 6: 10, Calvo AC, Moreno-Igoa M, Mancuso R. et al.
Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule, Copyright
(2011), [65] with permission from BioMed Central).
Apart from functional and survival results obtained in vivo in transgenic SOD1G93A mice, the
electrophysiological studies showed that, from three to four months of age, TTC treatment
played a partial protective effect as demonstrated by the lower decline in amplitudes of the
M waves, improvement in motor behavioral tests, and increased survival of motor neurons
in the TTC-treated animals’ lumbar spinal cord [64] (Figure 3).
Interestingly, TTC administration can also affect antiapoptic pathways by means of calcium-
related mechanisms [64]. The positive effects on motor neuron preservation, animal motor
function, and survival were confirmed with studies of anti-apoptotic effects and survival
signals in the spinal cords of treated animals. Transcriptional caspase-1 and caspase-3 levels
were downregulated in the spinal cord of TTC-treated animals as well as significant varia‐
tions in calcium-related gene expression were found [64]. Furthermore, a downregulation of
the caspase-3 activation protein levels in the spinal cord of TTC-treated animals indicated
that TTC might act through an anti-apoptotic pathway. Actually, Bax, Bcl2, phospho-Akt
and phospho-ERK 1/2 protein expression levels in TTC-treated animals were statistically
significant and close to those of wild-type animals, suggesting a decrease of apoptosis and a
lower degree of motor neuron neurodegeneration due to TTC treatment [64].
Taking all these results obtained in vitro and in vivo as a whole, non-viral gene therapy treat‐
ment based on TTC could be a safe and promising neuroprotective strategy for neurodege‐
nerative diseases, especially in ALS. However, the next question to be tackled is whether a
recombinant molecule of TTC may have a synergistic effect and enhance the neuroprotective
properties of TTC alone.
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Figure 3. Motor neuron survival and neurophysiological study in gastrocnemius and plantar muscles in SOD1G93A mice.
(a) Presence of TTC in the grey matter of the ventral horn of (a) positive control (SOD1G93A transgenic mice injected
with empty plasmid) and (b) SOD1G93A-TTC treated mice. Arrows point to some of the neurons positively stained for
TTC. Bar = 200 μm. (b) Electrophysiological study of compound muscle action potential (CMAP) in gastrocnemius and
plantar muscles in wild-type mice (WT), control SOD1G93A mice, and SOD1G93A mice treated with naked DNA encoding
for TTC. Values are the mean ± SEM. CMAP, compound muscle action potential; n, number of mice. *P < 0.05 vs. WT
group at the same age (Reprinted from Orphanet J. Rare Dis., 6: 10, Calvo AC, Moreno-Igoa M, Mancuso R. et al. Lack
of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule, Copyright (2011),
[65] with permission from BioMed Central).
3. Neuroprotective properties of recombinant molecules of TTC in a
mouse model of ALS
It has been very well described the specificity of a trophic factor for motoneurons and pre‐
cisely this specificity could be increased by genetically fusing it to TTC, while the trophic
factor could contribute to enhance the benefits observed for TTC. Therefore the next inevita‐
ble approach is to test naked-DNA gene delivery to encode for a chimeric molecule, to study
the potential synergistic effect.
As previously mentioned, BDNF belongs to the family of neurotrophins and binds specifi‐
cally to TrkB receptors to activate the intracellular signaling pathways that promote neuro‐
nal survival and the differentiation of neurons. The neurotrophic effects of BDNF on
motoneuronal degeneration have been widely studied in vitro and in vivo [66,67]. This neu‐
rotrophin has also been proposed as a potential therapeutic agent for the treatment of hu‐
man ALS [68], although no successful results have been achieved. This failure in the clinical
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application of BDNF may be due to the low efficacy of targeting the neurotrophic factor to
motoneurons. Alternatively, TTC possesses a high affinity for motoneurons [40], and the fu‐
sion of BDNF to the TTC protein might increase its accessibility. A previous study reported
that some neurotrophic factors, in particular BDNF, facilitate the internalization of TTC re‐
combinant molecules in motor nerve terminals [69]. In addition, TTC and the recombinant
protein BDNF-TTC can inhibit apoptosis in cultured neurons, with the quimeric molecule
being more effective than TTC alone [70]. Interestingly, BDNF may cause a relocalization of
membrane domains containing TTC receptors by activating Trk receptors, thereby facilitat‐
ing the neuronal internalization of TTC. This observation is supported by other authors who
state that TTC activates intracellular pathways involving Trk receptors [58]. Therefore, the
hypothesis of a synergistic positive effect based on the fusion of the mature form of BDNF
genes to TTC in a mouse model of ALS needs to be pointed out for the bench to the bedside
approach.
Similarly to the results observed in transgenic SOD1G93A mice [64], an amelioration of the de‐
cline in hindlimb muscle innervation was observed in the animals that were injected with
either naked DNA encoding TTC or naked DNA encoding the recombinant molecule TTC
and BDNF (BDNF-TTC) [65] (Figures 4,5), in addition to a significant delay in the onset of
symptoms and functional deficits (Figure 6), an improvement in the spinal motor neuron
survival (Figure 7) (down-regulation of caspase-1 and caspase-3 levels and a significant
phosphorylation of serine/threonine protein kinase Akt) (Figure 8) and a prolonged lifespan
under both treatments [64,65].
Figure 4. Motoneuronal preservation in transgenic SOD1G93A mice under TTC, BDNF and BDNF-TTC treatments. Immu‐
nohistochemical labeling for BDNF expression in the grey matter of the ventral horn of (a) positive control (SOD1G93A
transgenic mice injected with empty plasmid), (b) SOD1G93A-BDNF and (c) L2 and (d) L4 spinal segments of SOD1G93A-
BDNF-TTC mice. (e, f) Detail of BDNF immunolabeling of the sections shown in c and d, at higher magnification. Pres‐
ence of TTC in the grey matter of the ventral horn of (g) SOD1G93A-BDNF-TTC and (h) SOD1G93A-TTC treated mice.
Arrows point to some of the neurons positively stained for TTC. Bar = 200 μm in a, b, c, d, g and h; bar = 100 μm in e
and f (Reprinted from Orphanet J. Rare Dis., 6: 10, Calvo AC, Moreno-Igoa M, Mancuso R. et al. Lack of a synergistic
effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule, Copyright (2011), [65] with permis‐
sion from BioMed Central).
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Figure 5. Neurophysiological study in gastrocnemius and plantar muscles. (a) Results of wild-type mice (WT), control
SOD1G93A mice, and SOD1G93A mice treated with naked DNA encoding for BDNF, TTC, and BDNF-TTC are shown. Values
are the mean ± SEM. CMAP, compound muscle action potential; n, number of mice. *p < 0.05 vs. WT group at the
same age. (b) Histogram representation of the decrement in the amplitude of the compound muscle action potential.
CMAP was compared at 4 months with respect to values at 3 months of age in SOD1G93A mice, untreated and treated
with naked DNA encoding for BDNF, TTC or BDNF-TTC. For each group, the left bar corresponds to the gastrocnemius
muscle and the right bar to the plantar muscle (Reprinted from Orphanet J. Rare Dis., 6: 10, Calvo AC, Moreno-Igoa M,
Mancuso R. et al. Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion mole‐
cule, Copyright (2011), [65] with permission from BioMed Central).
Figure 6. Improvement in disease clinical outcomes in transgenic SOD1G93A mice under TTC, BDNF and BDNF-TTC treat‐
ments. Cumulative probability of the onset of disease symptoms (hanging-wire test) and survival in SOD1G93A mice injected
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at 60 days of age with TTC, BDNF-TTC, BDNF or empty (positive control) plasmids. Strength and motor function were tested
using the rotarod at 15 rpm. Mice were given up to 180 s for the test performance and the time at which mice fell was re‐
corded (*, #, +, P < 0.05; **, ##, P < 0.01; error bars indicate SEM); * for BDNF-TTC vs. positive control comparisons; # for TTC
vs. control comparisons; + for BDNF vs. positive control comparisons (Reprinted from Orphanet J. Rare Dis., 6: 10, Calvo AC,
Moreno-Igoa M, Mancuso R. et al. Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fu‐
sion molecule, Copyright (2011), [65] with permission from BioMed Central).
Figure 7. Spinal motor neuron survival of transgenic SOD1G93A mice under TTC, BDNF and BDNF-TTC treatments. Rep‐
resentative micrographs showing cross-sections of lumbar spinal cords stained with cresyl violet from wild-type, (a)
SOD1G93A control (positive control), (b) BDNF-treated, (c) and BDNF-TTC-treated, (d) mice at 16 weeks of age. Bar = 500
μm (Reprinted from Orphanet J. Rare Dis., 6: 10, Calvo AC, Moreno-Igoa M, Mancuso R. et al. Lack of a synergistic ef‐
fect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule, Copyright (2011), [65] with permission
from BioMed Central).
Figure 8. Apoptotic and survival pathways under TTC, BDNF and BDNF-TTC treatments. (a) Histogram representation
of the average number of stained motoneurons per section in L2 and L4 spinal cord segments of wild-type littermates,
control SOD1G93A and treated mice (n = 4-5 mice per group). * p < 0.05 vs. wild type; # p < 0.05 vs. SODG93A control
mice. (b) Fold-changes in the expression of pro-Casp3 and active Casp3 proteins, (c) Bax and Bcl2 proteins and (d)
phosphorylated states of Akt and ERK1/2 proteins in spinal cord lysates of control SOD1G93A animals (white) and ani‐
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mals treated with TTC (grey), BDNF-TTC (blue, BTTC) and BDNF (soft blue). Western blot quantities are shown as the
ratios to b-tubulin and then related to age-matched wild-type (black) mice data (*P < 0.05 and **P < 0.01 vs. control
SOD1G93A mice; ***p < 0.001; error bars indicate SEM) (Reprinted from Orphanet J. Rare Dis., 6: 10, Calvo AC, Moreno-
Igoa M, Mancuso R. et al. Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion
molecule, Copyright (2011), [65] with permission from BioMed Central).
Additionally, GDNF is another candidate neurotrophic factor for ALS therapy. This factor
has been described to show potent trophic effects on proliferation, differentiation and sur‐
vival of motor neurons in vitro and in vivo [63,71-76]. Furthermore, after the retrograde
transport of GDNF to the cell bodies, a fraction of this trophic factor avoided degradation
and was sorted to dendrites [51], similar to the known movement of the TTC [39]. It was also
suggested that the transsynaptic and transcytotic pathway used by GDNF was similar to
that of TTC, but not identical, and that GDNF protein degradation was lower than that of
TTC protein. Furthermore, the combination of TTC and GDNF has been evaluated in a neo‐
natal rat axotomy model [63] and in the ALS mouse model [77]. The combination of TTC
with insulin growth factor (IGF-1) has also been assayed in transgenic SOD1G93A mice [78],
although the effect of TTC alone has not been compared in any of these studies. When the
effect of TTC was compared to the recombinant molecule in vitro, a significant increase in
the survival capacity of neuronal cells was found [77]. However in vivo, no significant differ‐
ences were observed, which is probably due to the possibility that the recombinant molecule
might follow a GDNF route and not the TTC route under axotomy conditions [63].
When focusing the study in vivo in a mouse model of ALS, the recombinant molecule TTC
and GDNF (GDNF-TTC), GDNF and TTC treatments prompted a delay in disease onset, an
improvement in motor function and a longer lifespan in transgenic SOD1G93A mice, compar‐
ing to empty-plasmid injected control mice [79] (Figure 9).
Figure 9. Improvement in disease clinical outcomes in transgenic SOD1G93A mice under TTC, GDNF and GDNF-TTC
treatments. Cumulative probability of the onset of disease symptoms (hanging-wire test) and survival in SOD1G93A
mice injected at 60 days of age with TTC, GDNF-TTC, GDNF or empty (positive control) plasmids. Strength and motor
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function were tested using the rotarod at 15 rpm. Mice were given up to 180 s for the test performance and the time
at which mice fell was recorded (*, #, +, P < 0.05; **, ##, P < 0.01; error bars indicate SEM); *GDNF-TTC vs. control com‐
parisons; # TTC vs. control comparisons; + GDNF vs. control comparisons (*,#, +, P<0.05; **, ##, P<0.01; error bars indi‐
cate SEM) (Reprinted from Restor. Neurol. Neurosci, 30, Moreno-Igoa M, Calvo AC, Ciriza J. et al. Non-viral gene
delivery of the GDNF, either alone or fused to the C-fragment of tetanus toxin protein, prolongs survival in a mouse
ALS model, p. 69-80, Copyright (2012), [79] with permission from IOS Press).
Moreover, the recombinant molecule GDNF-TTC and full-length GDNF inhibited apoptotic
pathways in spinal cords of SOD1G93A mice by reducing the activation of caspase-3, as well
as Bax and Bcl2 protein levels reached a profile expression similar than the one observed in
wild type mice, highlighting the fact that treated mice biochemically resemble non-transgen‐
ic mice (Figure 10). In addition, all treatment molecules activated the PI3K survival pathway
by phosphorylating Akt and ERK1/2, resembling again the wild type levels [79] (Figure 10).
Figure 10. Apoptotic and survival pathways under TTC, GDNF and GDNF-TTC treatments. (a) Fold-changes in the ex‐
pression of GABA(A) receptor subunit-4 (Gabra4) mRNA levels in total spinal cord of wild type, control transgenic mice
and treated transgenic mice (n=5 per group). (*P<0.05, **P<0.01; error bars indicate SEM). Fold changes in the expres‐
sion of (b) pro-Casp3 and active Casp3 proteins, (c) Bax and Bcl2 proteins, and (d) phosphorylated states of Akt and
ERK1/2 proteins. Western blots from spinal cord lysates of control animals (white) and treated with TTC (gray),
GDNFTTC (hatched-columns) and GDNF (dotted-columns). Western blot quantities are shown as the ratio to β-tubulin
and then related to age-matched wild type (black) mice data (Reprinted from Restor. Neurol. Neurosci, 30, Moreno-
Igoa M, Calvo AC, Ciriza J. et al. Non-viral gene delivery of the GDNF, either alone or fused to the C-fragment of teta‐
nus toxin protein, prolongs survival in a mouse ALS model, p. 69-80, Copyright (2012), [79] with permission from IOS
Press).
Summarizing, albeit a significant improvement in behavioral assays together with an activa‐
tion of anti-apoptotic and survival pathways under BDNF and GDNF treatments was ob‐
served in transgenic SOD1G93A mice, no synergistic effect was found neither using the BDNF-
TTC nor GDNF-TTC recombinant molecules. Interestingly, recombinant plasmids BDNF-
TTC and GDNF-TTC were detected in skeletal muscle and the corresponding recombinant
protein reached the spinal cord tissue of transgenic SOD1G93A mice (Figure 11), reinforcing
the carrier properties of TTC.
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As a final point, the active state of the neurotrophic factors BDNF and GDNF in the recombi‐
nant molecule could suggest that either BDNF or GDNF could exert an autocrine and neuro‐
protective role together with TTC to a similar extent as TTC alone; however this effect could
not be sufficient enough to prompt a synergistic effect. As a consequence, the recombinant
molecules could mainly use the same pathway that mimics a neurotrophic secretion route,
prompting survival signals in the spinal cord of transgenic SOD1G93A mice [65,79]. Despite
all these contributions to the understanding of the neuroprotective properties of recombi‐
nant molecules, it is undoubtedly that TTC has open the door to an alternative therapeutic
strategy for more neurodegenerative diseases although its molecular pathways is not yet
well characterized.
Figure 11. TTC and BDNF detection in skeletal muscle and spinal cord of ALS transgenic SOD1G93A mice. Western blot
detection of TTC in spinal cord and skeletal muscle tissues of wild-type (C-, negative control), SOD1G93A transgenic mice
injected with empty plasmid (C+, positive control), TTC- and BDNFTTC (BTTC)-treated mice. In TTC and BDNF-TTC treat‐
ed groups, the detected band was approximately of 50 and ~ 70 KDa respectively (*), using both anti-TTC and anti-
BDNF antibodies. In the BDNF group, the dimeric conformation, indicated by arrows, was observed at approximately
40 KDa (Reprinted from Orphanet J. Rare Dis., 6: 10, Calvo AC, Moreno-Igoa M, Mancuso R. et al. Lack of a synergistic
effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule, Copyright (2011), [65] with permis‐
sion from BioMed Central).
4. Conclusions
At present, gene and stem cell therapies are holding the hope for an efficient treatment in
ALS. Regarding gene therapy, the possibility of delivering therapeutic molecules to dam‐
aged tissues crossing the blood-brain barrier has made possible the study of viral (adenovi‐
rus, adeno-associated and lentivirus) and non-viral (fragment C of tetanus toxin) vectors,
which are retrogradely transported to motor neurons, in preclinical animal models showing
promising neuroprotective effects.
Although therapeutic strategies, which tend to stop or slow down the progression of ALS,
are one of the main goals in this field of research, the new property of TTC has opened the
door to new non-viral therapeutic strategies in this disease. The fact that TTC as well as the
recombinant molecules BDNF-TTC and GDNF-TTC can be transported through motoneur‐
ons to induce a later onset of symptoms, improve motoneuron survival and extend the sur‐
vival of SOD1G93A mice support the fact that the naked DNA-mediated intramuscular
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delivery of TTC and fusion molecules can promote neuroprotective effects in the SOD1G93A
murine model of ALS. The active states of BDNF and GDNF in the recombinant molecules
also confirm that these neurotrophic factors could exert an autocrine and neuroprotective
role together with TTC to a similar extent as TTC alone, but this effect was not sufficient to
enhance the survival signals observed under TTC treatment alone.
Definitively, the neuroprotective role of fragment C has shed light on the understanding of
the disease neurodegeneration processes and the study of this promising property of TTC
can be extended to other neurodegenerative diseases, such as Parkinson’s disease, Alzheim‐
er’s disease and Spinal Muscular Atrophy (SMN). Essentially, a better understanding of
these neurodegenerative diseases will facilitate the translation from animal model to pa‐
tients to find a definitive therapeutic approach.
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